Interleukin-12 expression stimulants - Pipeline Insight, 2024

This “Interleukin-12 expression stimulants - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Interleukin-12 expression stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Interleukin-12 expression stimulants Understanding

Interleukin-12 expression stimulants: Overview

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Interleukin 12, or IL-12, is a cytokine (a type of signaling protein) that activates the immune system after being released from cells. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest. Diverse IL-12 delivery systems, from immunocytokine fusions to polymeric nanoparticles, have demonstrated robust antitumor immunity with reduced adverse events in preclinical studies. Perspectives on how IL-12-based immunotherapies may be utilized for widespread clinical application in the very near future are offered.

Interleukin-12 expression stimulants - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interleukin-12 expression stimulants pipeline landscape is provided which includes the disease overview and Interleukin-12 expression stimulants treatment guidelines. The assessment part of the report embraces, in depth Interleukin-12 expression stimulants commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interleukin-12 expression stimulants collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-12 expression stimulants R&D. The therapies under development are focused on novel approaches to treat/improve Interleukin-12 expression stimulants.

Interleukin-12 expression stimulants Emerging Drugs Chapters

This segment of the Interleukin-12 expression stimulants report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-12 expression stimulants Emerging Drugs

T3011: Immvira Pharma Imm Vira's MVR-T3011 oncolytic virus program has innovated with a genetically engineered oncolytic herpes simplex virus-1 (o HSV-1) to enhance the known oncolytic effects of o HSV-1. Through gene recombinant technologies, PD-1 antibody and interleukin-12 immune modulators are expressed within the virus. Oncolysis is achieved with additional immune response stimulation while keeping the boosted immune activity limited to the locality of MVR-T3011 to achieve a potentially favorable safety profile. The MVR-T3011 intratumoral program aims to target most solid malignant tumors with both remission rate improvement and safety improvement over immune modulator monotherapies. In January 2020, ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies. It is currently being evaluated in Phase II stage of development for the treatment of Breast cancer and Headandneckcancer.

INXN 2001: Ziopharm Oncology INXN 2001 is injected intratumourally, and employs an adenoviral vector to directly deliver a gene, which expresses interleukin-12 (IL-12). An oral activator ligand (INXN 1001, veledimex) is then given to turn on expression of the gene locally. INXN-2001 is in phase II clinical trials with Veledimex by ZIOPHARM Oncology for the treatment of recurrent/metastatic breast cancer and phase I for glioblastoma or malignantglioma.

Interleukin-12 expression stimulants: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-12 expression stimulants drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Interleukin-12 expression stimulants

There are approx. 8+ key companies which are developing the therapies for Interleukin-12 expression stimulants. The companies which have their Interleukin-12 expression stimulants drug candidates in the most advanced stage, i.e. phase II include Immvira Pharma.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Interleukin-12 expression stimulants pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-12 expression stimulants: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-12 expression stimulants therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-12 expression stimulants drugs.

Interleukin-12 expression stimulants Report Insights

• Interleukin-12 expression stimulants Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Interleukin-12 expression stimulants Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Interleukin-12 expression stimulants drugs?
• How many Interleukin-12 expression stimulants drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interleukin-12 expression stimulants?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interleukin-12 expression stimulants therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interleukin-12 expression stimulants and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.